Observational studyBMC pediatrics2026
Sustained seropositivity up to eight years after two-dose inactivated hepatitis A vaccination in Turkish children: a retrospective observational study.
Observational study in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTürkiye introduced a two-dose inactivated hepatitis A vaccination program in 2012 as part of the national childhood immunization schedule. However, data on the long-term persistence of vaccine-induced immunity in Turkish children remain limited. This study aimed to evaluate the durability of anti-HAV IgG responses following routine childhood hepatitis A vaccination.
methodsA retrospective cross-sectional study was conducted including 551 children who completed the two-dose hepatitis A vaccination schedule and 481 age-matched unvaccinated children. Vaccination status and anti-HAV IgG antibody levels were obtained from electronic hospital records. Serological testing was performed using a chemiluminescence microparticle immunoassay. Anti-HAV IgG levels ≥ 1 mIU/mL were considered protective.
resultsAnti-HAV IgG seropositivity was 97.8% among vaccinated children. Seropositivity rates remained high over time but showed a gradual decline from 99.4% in the first year to 90.0% in the eighth year after vaccination. Despite this decrease, the majority of vaccinated children remained seropositive throughout the follow-up period. In contrast, seropositivity was 38.7% in the unvaccinated group, reflecting natural exposure to hepatitis A virus in the population. Because of the retrospective cross-sectional design, longitudinal antibody changes, clinically confirmed hepatitis A cases, and possible silent HAV infections could not be systematically evaluated.
conclusionsOur findings demonstrate that a two-dose inactivated hepatitis A vaccination schedule provides sustained serological protection for up to eight years in Turkish children. Although anti-HAV antibody levels gradually declined over time, seropositivity rates remained high throughout the study period, suggesting persistence of immunological protection. The maintenance of immune memory despite decreasing antibody concentrations may contribute to continued protection. Further long-term prospective studies evaluating both humoral and cellular immune responses are needed to better define the duration of protection and assess the potential need for booster vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.